This increase in brain sulphamidase activity levels led to quantifiable improvement in brain pathology and behavior outcomes in the mouse model of MPS-IIIA (Sorrentino et al., 2013). This evidence concerns the gene SGSH and mucopolysaccharidosis type 3A.